Upstream Bio, Inc. (UPB) Form 8-K — May 13, 2026
Upstream Bio, Inc. (UPB) reported financial results for the first quarter ended March 31, 2026. The company had a cash position of $294.6 million, which is expected to fund operations through 2027. Research and development expenses increased to $36.6 million for the quarter, up from $25.8 million in the same period in 2025, primarily due to increased clinical and manufacturing expenses for verekitug programs.
Key figures
- Eps
- 0
- Eps Beat
- 0
- Revenue
- 1034
- Guidance
- Cash, cash equivalents and short-term investments of $294.6 million are expected to fund planned operations through 2027.
- Total Debt
- 14059
- Total Assets
- 353772
- Cash Position
- 294600
- Shares Outstanding
- 0
Price after filing
1 day: -6.1%7 days: -10.1%30 days: -31.8%
Close on the filing date to close N calendar days later (from $9.36). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.